Russia facing shortage of ED drug Viagra

28 February 2023

Russia may be facing a shortage of erectile dysfunction drug Viagra (sildenafil) – once the best-selling medicine in the country- due to the recent announcement by the USA’s Viatris (Nasdaq: VTRS) about the suspension of supplies to the drug to the Russian market.

Viatris has already informed the Russian Ministry of Industry and Trade about the suspension of supplies of the drug, which is not localized in Russia, reports The Pharma Letter’s local correspondent.

Originated by US pharma giant Pfizer (NYSE: PFE), in recent years Viagra has long lost its leadership to its direct rivals in the ED market segment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK